Drug Toxicity Flashcards

1
Q

How is drug toxicity assessed?

A
  • idea of tox from lab animal studies
  • once therapuetuc dose decided, target animal species safety studies undertaken in young animals
  • if used in FPAs then lifetime safety studies in lab animals to assess chronic effects and placental transfer etc.
  • field safety and efficacy studies done (sick animals), all adverse effects recorded (not placebo controlled so adverse effects not necesarily d/t drug, just looking for trends)
  • periodic safety update reports filed for 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why is drug tox seen in vet?

A
  • off label usege
  • animals not clones of original animals used for testing
  • mistakes in calculating,s toring and handling drugs
  • animals with multiple dz -> drug interactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What happens to tetracyclines if stored in subnlight?

A

Decay

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Define adverse drug reactions

A
  • unwanted effects when drugs administered for therapeutic purpose
  • +- lack of efficacy in a pateitn where you would have expected the drug to wor k
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Classifications of ADRs?

A

A: predictable from knowledge of drug actions (eg. B blockers -> bradycardia, ACE inhibitors -> acute renal failure, sulphonylurea drugs -> hypoglycaemia)
B: either
> predictable= not related to mechanism of action but predictable indirectly (eg. chronic use of doxorubicin -> muscle damage, aminoglycosides -> PCT necrosis, prednisolone -> hepatopathy)
> unpredictable/idiosyncratic (eg. chloramphenicol -> aplastic anaemia, phenylbutazone -> agranulocytosis, phenytoin -> hepatitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Why is PCT necrosis seen with chronic aminoglycoside usage?

A

transported actively into PCT cells and not transported out again
- also means residues stay for long time in FPA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why is hepatopathy seen with chronic prednisolone administration?

A
  • glycogen accumulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How are idiosyncratic reactions detected?

A
  • incidence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What factors may enhance ADR?

A
  • age/breed/gender/pregnant?
  • dz status (esp hepatic, renal, CV)
  • concominant use of other drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does drug use in neonates differ from adults? eg. of clinical implications of this?

A
  • different and changing physiology
  • v gut motility, under developed gut flora and mucosal enzymies (^ absorption)
  • ^ total body water (^volume of distribution)
  • immature liver enzymes
  • v GFR ~3-6months becomes = adult
    > eg. theophylline in puppies needs ^ dose (larger volume of distrubtion) but less frequently (delayed elimination)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Empirical advice for drug use in neonates

A
  • avoid drugs in
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

give 2 specific examples of toxicity specific to neonates

A

> fluoroquinolones damage articular cartilage

> tetracyclines disclour teeth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does drug use in geritrics differ?

A

^ risk ADR because..

  • smaller body size
  • poor nutritional status
  • presence multiple diseases-
  • altered complcance
  • age related organ dysfunction eg. renal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which drugs have ^ risk toxicity with subclinical renal impairment in humans?

A
  • low TI eg. procainamide, digoxin, gentamicin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which drugs are affected by decreased lean body mass?

A

cimetidine (for gastric ulcers) ^ plasma levels of polar drugs with v fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How may breed be a risk factor for ADRs?

A
  • sensitivity usually d/t difference in pharmacokinetics

- idiosyncratic reactions may be d/t genetic polymorphisms

17
Q

Gve an eg. of a specific ADR in horses. When may this be seen? Clinical signs?

A

> Monensin toxicity

  • sheep growth promoter (included in sheep pellets)
  • clinical signs associated with neuronal, skeletal and cardiac effects of ionophores
  • likely susceptibility d/t low first pass metabolism in horses cf. ruminants -> ^ bioavailability compared to sheep.
  • horses eating sheep pellets -> toxicity
18
Q

Eg of toxicity in cats

A
  • pyrethrum insecticide
  • more sensitve to over the counter flea products ro dogs
  • ineffective metabolism
  • hyper-excitablility -> convulions and suden death
  • ^ inceidence despite labels sayng toxic o cats!
19
Q

eg of toxicity in dogs

A
  • Ivermectin in collie- type dogs PGP efflux pump for drugs (expressed in tumour cells-> insensitivity to chemo)
  • also expressed in other tissues
  • detection of PGP product of MDRI gene
  • also transports ivermectin, loperamide, vincristine, cyclsporine A.
20
Q

How can protein bound drugs interact? EEgs protein bound drugs?

A
  • if highly albumen bound they will displace each other -> ^ free concentration of the drug and more intense actions
  • eg. potentiated sulphonamides and bute IV in LA - cardiac arrythmia, syncope and death.